Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USA
Tóm tắt
Từ khóa
Tài liệu tham khảo
Rose MA, Vukicevic M, Koklanis K. Adherence of patients with diabetic macular oedema to intravitreal injections: a systematic review. Clin Exp Ophthalmol. 2020;48(9):1286–98.
Salem W, Fraser-Bell S, Gillies M. Clinical development of new treatments for diabetic macular oedema. Clin Exp Optom. 2012;95(3):297–305.
Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis. 2015;2:17.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–31.
Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin. 2010;26(7):1587–97.
Varma R, Bressler NM, Doan QV, et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014;132(11):1334–40.
Li JQ, Welchowski T, Schmid M, et al. Prevalence, incidence and future projection of diabetic eye disease in Europe: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(1):11–23.
Ho AC, Scott IU, Kim SJ, et al. Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology. 2012;119(10):2179–88.
Jusufbegovic D, Mugavin MO, Schaal S. Evolution of controlling diabetic retinopathy: changing trends in the management of diabetic macular edema at a single institution over the past decade. Retina. 2015;35(5):929–34.
Lally DR, Shah CP, Heier JS. Vascular endothelial growth factor and diabetic macular edema. Surv Ophthalmol. 2016;61(6):759–68.
Petrella RJ, Blouin J, Davies B, Barbeau M. Prevalence, demographics, and treatment characteristics of visual impairment due to diabetic macular edema in a representative Canadian cohort. J Ophthalmol. 2012;2012: 159167.
Weiss M, Sim DA, Herold T, et al. Compliance and adherence of patients with diabetic macular edema to intravitreal anti-vascular endothelial growth factor therapy in daily practice. Retina. 2018;38(12):2293–300.
Zhou B, Mitchell TC, Rusakevich AM, Brown DM, Wykoff CC. Noncompliance in prospective retina clinical trials: analysis of factors predicting loss to follow-up. Am J Ophthalmol. 2020;210:86–96.
Kiss S, Chandwani HS, Cole AL, Patel VD, Lunacsek OE, Dugel PU. Comorbidity and health care visit burden in working-age commercially insured patients with diabetic macular edema. Clin Ophthalmol. 2016;10:2443–53.
Ehlken C, Helms M, Böhringer D, Agostini HT, Stahl A. Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients. Clin Ophthalmol. 2017;12:13–20.
Butler AMNK, Overman RA, Brookhart MA. IBM MarketScan research databases. In: Sturkenboom MST, editor. Databases for pharmacoepidemiological research springer series on epidemiology and public health. Cham: Springer; 2021. p. 243–51.
National Center for Health Statistics. Centers for Disease Control and Prevention. Classification of diseases, functioning, and disability. https://www.cdc.gov/nchs/icd/. Accessed 24 Nov 2021.
U.S. Food & Drug Administration. National Drug Code Directory. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory. Accessed 24 Nov 2021.
Schneeweiss S, Rassen JA, Brown JS, et al. Graphical depiction of longitudinal study designs in health care databases. Ann Intern Med. 2019;170(6):398–406.
Danaei G, Tavakkoli M, Hernan MA. Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol. 2012;175(4):250–62.
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna; 2017. https://www.r-project.org/.
Peto T, Akerele T, Sagkriotis A, Zappacosta S, Clemens A, Chakravarthy U. Treatment patterns and persistence rates with anti-VEGF treatment for diabetic macular edema in the UK: a real-world study. Diabet Med. 2022;39(4):e14746.
Bhandari S, Nguyen V, Fraser-Bell S, et al. Ranibizumab or aflibercept for diabetic macular edema: comparison of 1-year outcomes from the Fight Retinal Blindness! registry. Ophthalmology. 2020;127(5):608–15.
Rosenblatt TR, Rayess N, Al-Moujahed A, Khurana RN, Mruthyunjaya P. Discontinuation and loss to follow-up rates in clinical trials of intravitreal anti-vascular endothelial growth factor injections. Graefes Arch Clin Exp Ophthalmol. 2022;260(1):93–100.
Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and health care resource use among commercially insured non-elderly patients with diabetic macular edema. Ophthalmic Surg Lasers Imaging Retina. 2015;46(7):744–51.
Kim EJ, Lin WV, Rodriguez SM, Chen A, Loya A, Weng CY. Treatment of diabetic macular edema. Curr Diab Rep. 2019;19(9):68.
The Henry J. Kaiser Family Foundation. Health insurance coverage of the total population. http://kff.org/other/state-indicator/total-population/. Accessed 24 Nov 2021.
Giocanti-Auregan A, Tadayoni R, Grenet T, et al. Estimation of the need for bilateral intravitreal anti-VEGF injections in clinical practice. BMC Ophthalmol. 2016;16:142.